Bopedacol injection, which once became the most expensive drug in China at a price of 2.79 million yuan per dose, finally welcomed the first patient to use it after reducing the price by 1.4 million yuan in June of this year. On September 9, the reporter learned from the R&D manufacturer Xinji Pharmaceutical that Xinjiuning recently issued the country's first prescription in Tianjin. Xinjiuning is a gene therapy for moderate to severe hemophilia B. It was independently developed by a Chinese company. It is also the first adeno-associated virus vector gene therapy to be marketed domestically. It was approved for sale in China in April 2025.

Bopedacol injection, which once became the most expensive drug in China at a price of 2.79 million yuan per dose, finally welcomed the first patient to use it after reducing the price by 1.4 million yuan in June of this year. On September 9, the reporter learned from the R&D manufacturer Xinji Pharmaceutical that Xinjiuning recently issued the country's first prescription in Tianjin. Xinjiuning is a gene therapy for moderate to severe hemophilia B. It was independently developed by a Chinese company. It is also the first adeno-associated virus vector gene therapy to be marketed domestically. It was approved for sale in China in April 2025.